These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 15199346)

  • 1. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction.
    Sinnaeve PR; Alexander JH; Bogaerts K; Belmans A; Wallentin L; Armstrong P; Adgey JA; Tendera M; Diaz R; Soares-Piegas L; Vahanian A; Granger CB; Van De Werf FJ
    Am Heart J; 2004 Jun; 147(6):993-8. PubMed ID: 15199346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
    Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators
    Lancet; 2001 Aug; 358(9282):605-13. PubMed ID: 11530146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab.
    Dubois CL; Belmans A; Granger CB; Armstrong PW; Wallentin L; Fioretti PM; López-Sendón JL; Verheugt FW; Meyer J; Van de Werf F;
    J Am Coll Cardiol; 2003 Oct; 42(7):1178-85. PubMed ID: 14522476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction.
    Kaul P; Armstrong PW; Cowper PA; Eisenstein EL; Granger CB; Van de Werf F; Mark DB
    Am Heart J; 2005 Apr; 149(4):637-44. PubMed ID: 15990746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction.
    Wallentin L; Goldstein P; Armstrong PW; Granger CB; Adgey AA; Arntz HR; Bogaerts K; Danays T; Lindahl B; Mäkijärvi M; Verheugt F; Van de Werf F
    Circulation; 2003 Jul; 108(2):135-42. PubMed ID: 12847070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial.
    Antman EM; Louwerenburg HW; Baars HF; Wesdorp JC; Hamer B; Bassand JP; Bigonzi F; Pisapia G; Gibson CM; Heidbuchel H; Braunwald E; Van de Werf F
    Circulation; 2002 Apr; 105(14):1642-9. PubMed ID: 11940541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3).
    Curtis JP; Alexander JH; Huang Y; Wallentin L; Verheugt FW; Armstrong PW; Krumholz HM; Van de Werf F; Danays T; Cheeks M; Granger CB;
    Am J Cardiol; 2004 Aug; 94(3):279-83. PubMed ID: 15276088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction.
    Armstrong PW; Wagner G; Goodman SG; Van de Werf F; Granger C; Wallentin L; Fu Y;
    Eur Heart J; 2003 Aug; 24(16):1515-22. PubMed ID: 12919776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous enoxaparin following thrombolysis and intravenous unfractionated heparin in ST-elevation acute myocardial infarction: safety and efficacy of low vs full dose.
    Rubboli A; Gatti C; Spinolo L; Parollo R; Spitali G; Maresta A
    Minerva Cardioangiol; 2006 Feb; 54(1):131-7. PubMed ID: 16467747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
    Topol EJ;
    Lancet; 2001 Jun; 357(9272):1905-14. PubMed ID: 11425410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS.
    Sinnaeve PR; Huang Y; Bogaerts K; Vahanian A; Adgey J; Armstrong PW; Wallentin L; Van de Werf FJ; Granger CB;
    Am Heart J; 2006 Oct; 152(4):684.e1-9. PubMed ID: 16996833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenecteplase: new preparation. Another thrombolytic agent for myocardial infarction: a slightly simpler treatment.
    Prescrire Int; 2002 Jun; 11(59):83-4. PubMed ID: 12068843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
    Wallentin L; Bergstrand L; Dellborg M; Fellenius C; Granger CB; Lindahl B; Lins LE; Nilsson T; Pehrsson K; Siegbahn A; Swahn E
    Eur Heart J; 2003 May; 24(10):897-908. PubMed ID: 12714021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
    Lincoff AM; Califf RM; Van de Werf F; Willerson JT; White HD; Armstrong PW; Guetta V; Gibler WB; Hochman JS; Bode C; Vahanian A; Steg PG; Ardissino D; Savonitto S; Bar F; Sadowski Z; Betriu A; Booth JE; Wolski K; Waller M; Topol EJ;
    JAMA; 2002 Nov; 288(17):2130-5. PubMed ID: 12413372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
    Ellis SG; Armstrong P; Betriu A; Brodie B; Herrmann H; Montalescot G; Neumann FJ; Smith JJ; Topol E;
    Am Heart J; 2004 Apr; 147(4):E16. PubMed ID: 15077099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators.
    Antman EM; Gibson CM; de Lemos JA; Giugliano RP; McCabe CH; Coussement P; Menown I; Nienaber CA; Rehders TC; Frey MJ; Van der Wieken R; Andresen D; Scherer J; Anderson K; Van de Werf F; Braunwald E
    Eur Heart J; 2000 Dec; 21(23):1944-53. PubMed ID: 11071800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data.
    Armstrong PW; Chang WC; Wallentin L; Goldstein P; Granger CB; Bogaerts K; Danays T; Van de Werf F;
    CMAJ; 2006 May; 174(10):1421-6. PubMed ID: 16682709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
    Cohen M; Gensini GF; Maritz F; Gurfinkel EP; Huber K; Timerman A; Krzeminska-Pakula M; Danchin N; White HD; Santopinto J; Bigonzi F; Hecquet C; Vittori L;
    J Am Coll Cardiol; 2003 Oct; 42(8):1348-56. PubMed ID: 14563573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Confusion in reperfusion.
    Gibson CM
    J Am Coll Cardiol; 2003 Oct; 42(7):1186-7. PubMed ID: 14522477
    [No Abstract]   [Full Text] [Related]  

  • 20. One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction.
    Sinnaeve P; Alexander J; Belmans A; Bogaerts K; Langer A; Diaz R; Ardissino D; Vahanian A; Pehrsson K; Armstrong P; Van de Werf F;
    Am Heart J; 2003 Jul; 146(1):27-32. PubMed ID: 12851604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.